Autodesk, Inc. (NASDAQ:ADSK) last session’s volume of 2.57 million shares was higher than its average volume of 2.35 million shares. The stock, after opening at $105.5, hit $104.88 through the close by scoring -0.66%.

Autodesk, Inc. (ADSK) Analyst Opinion

Autodesk, Inc. has a consensus outperform rating from 22 Wall Street analysts, and the number of shares currently sold short amount to at least 2.46% of shares outstanding. The stock spiked 11.61% last month and is up 41.71 this year. Wall Street is only getting more bullish on the stock, with 17 of analysts who cover ADSK having a buy-equivalent rating. Analysts have placed a $113.05 price target on Autodesk, Inc., suggesting a 7.79% gain from recent close. It’s currently trading about -8.55% below its 52-week high.

Autodesk, Inc. Earnings Surprise

Autodesk, Inc. (ADSK) surprised the stock market in its last reported earnings when it earned -$0.16 a piece versus the consensus-estimated -$0.24. Its revenue totaled $470.4 million down -1.75% from the previous quarter.

Autodesk, Inc. (NASDAQ:ADSK) Intraday View

This stock (ADSK) is ahead of its 52-week low with 110.52%. Its last month’s stock price volatility remained 3.78% which for the week stands at 2.87%. The share price has moved backward from its 20 days moving average, trading at a distance of -4.64% and stays 6.77% away from its 50 days moving average. Over the last five days, shares have faced -1.01% losses and now is up 27.15% since hitting its 200-day moving average of $87.84. Autodesk, Inc. (ADSK) has made its way to a 12-month gain of 84.75%.

Turning to Second Sight Medical Products, Inc. (NASDAQ:EYES), its shares were trading at $1.1 a retreat of $-0.05, on the trading floor. The stock, after opening at $1.16, touched a high of $1.17 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. Second Sight Medical Products, Inc. has 0 buy ratings, 0 holds and 0 sells even after the stock tumbled -75.82% from its high of $4.55 to a $64.8 million market value through last close.

Second Sight Medical Products, Inc. (EYES) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 2 to 2 during a month. Analysts set a 12-month price target of $5 a share. The target implies a 354.55% spike from where the shares are currently trading. Also, the current price highlights a discount of 354.55% to analysts’ high consensus price target.

Second Sight Medical Products, Inc. (NASDAQ:EYES) Intraday Trading

The counter witnessed a trading volume of 0.28 million shares versus an average volume of 0.52 million shares during last trading session. Its last month’s stock price volatility remained 4.28% which for the week approaches 3.85%. The lowest price the stock reached in the last trading day was $1.1 and compares with the $1.06 52-week low. The stock recovered 3.77% since its low point and has performed -44.16% year-to-date.